NASDAQ$NAMS
NewAmsterdam Pharma Company NV · Q4 2024 earnings
Q4 2024 earnings · · Before market open · Investor relations
Briefing
NewAmsterdam Pharma reported its full year 2024 financial results, highlighting significant progress in clinical development and a strong financial position.
NewAmsterdam Pharma reported a net loss of $241.6 million for the full year 2024, an increase from $176.9 million in 2023. The company's revenue increased to $45.6 million in 2024 from $14.1 million in 2023, primarily due to a clinical success milestone and development cost reimbursement. Cash and cash equivalents significantly increased to $771.7 million by year-end 2024, driven by successful financing rounds.
- NewAmsterdam Pharma reported a full-year 2024 net loss of $241.6 million, compared to $176.9 million in 2023.
- Full-year 2024 revenue increased to $45.6 million from $14.1 million in 2023, driven by a clinical success milestone and development cost reimbursement.
- Cash and cash equivalents, along with marketable securities, totaled $834.2 million as of December 31, 2024, a substantial increase from $340.5 million in 2023.
- The company completed enrollment for the PREVAIL Phase 3 CVOT trial in April 2024 and expects EMA submission in 2H25.
Headline financials
Revenue & EPS history
NewAmsterdam Pharma · Revenue · Quarterly
$45.6M
Forward guidance
NewAmsterdam Pharma anticipates continued progress in clinical development and regulatory interactions, with an EMA submission expected in the second half of 2025. The company is also focusing on launch readiness for obicetrapib in the U.S. and Europe, if approved, supported by strong financial capital.
Tailwinds
- EMA submission for obicetrapib expected in 2H25 by partner Menarini.
- Additional data from BROADWAY, BROOKLYN, and TANDEM trials to be presented throughout 2025.
- Phase 3 PREVAIL CVOT remains on track with enrollment completed in April 2024.
- Increasing focus and efforts on launch readiness, including scaling up inventory and commercial capabilities.
- Sufficient capital to fund operations beyond PREVAIL CVOT readout and commercial launch in the U.S.
Headwinds
- Regulatory approval is not guaranteed and is subject to review processes.
- Commercial launch is contingent on regulatory approval.
- The company's financial performance is subject to market, financial, political, and legal conditions.
- Competition from other product candidates could impact future business.
- Ability to obtain sufficient supply of materials and retain qualified personnel are ongoing risks.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 17 quarterly earnings reports · overlaid with Q4 2024
+0.8%
Avg return
Earnings day
+3.0%
Avg return
5 days after
-0.6%
Avg return
30 days after
59%
10 / 17 earnings
Positive
+18.2%
Q3 2024
Best reaction
-9.6%
Q1 2024
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | +1.2% | +25.4% | +1.5% | |
| Q4 2025 | -3.0% | +2.6% | -17.9% | |
| Q3 2025 | +4.3% | +6.7% | -3.5% | |
| Q1 2025 | +1.2% | -8.3% | -3.2% | |
| Q4 2024 | +10.2% | +13.4% | +21.7% | |
| Q3 2024 | +18.2% | +28.4% | -4.2% | |
| Q1 2024 | -9.6% | -12.1% | -7.8% | |
| Q2 2023 | -5.7% | -4.9% | -2.4% | |
| Q4 2023 | -5.7% | -4.9% | -2.4% | |
| Q1 2023 | +0.3% | +2.0% | -0.9% | |
| Q4 2022 | +2.1% | +1.7% | +7.4% | |
| Q3 2022 | -0.1% | +0.1% | +0.8% | |
| Q2 2022 | +0.1% | +0.1% | +0.4% | |
| Q1 2022 | +0.0% | +0.1% | +0.3% | |
| Q3 2021 | -0.3% | +0.2% | -0.1% | |
| Q2 2021 | +0.2% | +0.2% | -1.2% | |
| Q1 2021 | +0.1% | +0.2% | +1.0% | |
| Q4 2020 | — | — | — | |
| Q3 2020 | — | — | — | |
| Q2 2020 | — | — | — | |
| Q1 2020 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro